Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity-Reference-Cited by-同舟云学术

Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity

Published:2024-04 Issue: Volume:183 Page:61-67
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Passarelli Anna,Carbone Vittoria,Pignata Sandro,Mazzeo Roberta,Lorusso Domenica,Scambia Giovanni,Canova Stefania,Di Palma Teresa,Tasca Giulia,Mantiero Mara,Naglieri Emanuele,Andreetta Claudia,Rauso Martina,Brunetti Anna Elisabetta,Laera Letizia,Abeni Chiara,Scandurra Giuseppa,Gambaro Anna Rita,Pastore Alessia,Bengala Carmelo,Gunnellini Marco,Farolfi Alberto,Spinello Maurizio,Bartoletti Michele

Funder

Novartis Farmacéutica

Publisher

Elsevier BV

Reference36 articles.

1. The cancer genome atlas pan-cancer analysis project;The Cancer Genome Atlas Research Network;Nat. Genet.,2013

2. Integrated genomic characterization of endometrial carcinoma;The Cancer Genome Atlas Research Network;Nature,2013

3. Integrated genomic analyses of ovarian carcinoma;Cancer Genome Atlas Research Network;Nature,2011

4. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

5. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Oaknin;Ann. Oncol.,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular substratification of endometrial carcinomas with no special molecular profile (NSMP) by using a limited NGS custom panel may facilitate effective patient selection for the PIK3CA-targeted therapy;Virchows Archiv;2024-09-05